Truist Archives - In Class Book

May 1, 2023

WEX Inc. Receives Price Objective Boost from Truist Financial Analysts Amidst Successful Quarter and Fintech Innovation

As of April 29th, 2023, economic engineering business WEX Inc. (NYSE:WEX) gained a price objective improve from Truist Money analysts. The new goal is established at $190.00, which implies a 9.64{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} opportunity upside from the prior near.

According to their newest earnings report on February 9th, WEX had a prosperous quarter with $618.61 million in earnings in comparison to the believed $575.79 million by analysts. The organization providers supplier also claimed a financial gain of $3.04 EPS for the quarter, exceeding anticipations by $.27.

WEX operates as a result of a few segments: Fleet Alternatives, Travel and Company Options, and Health and fitness and Staff Profit Options. The Fleet Alternatives section focuses on fleet car payment processing providers that consist of buyer products and services, account activation and retention products and services, merchant options, analytics tools, and ancillary services.

With a return on equity of 30.31{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} and a internet margin of 8.57{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}, WEX continues to impress both traders and analysts with its financial general performance in an at any time-evolving business.

The increase of monetary technologies has revolutionized the way corporations manage their transactions and functions around the world. Corporations like WEX have been instrumental in giving creative solutions that increase effectiveness and cut down costs for their customers.

Investments in fintech companies like WEX have develop into more desirable since of their ground breaking offerings for firms seeking to streamline their company procedures without compromising excellent services.

With promote-side analysts predicting an EPS of 12.21 for this calendar year by WEX, it is crystal clear that this economical know-how huge is flourishing as we head into new economic frontiers pushed by technological improvement.

As the earth proceeds to innovate all around electronic currencies, on line marketplaces, cloud-centered methods integration equipment, blockchain platforms amid some others we can count on organizations like WEX to retain offering nimble answers to existing troubles whilst carving out the next frontier for fintech innovation.

WEX Inc: Driving Toward a Vibrant Upcoming

WEX Inc: A Promising Long term Forward

WEX Inc (NYSE: WEX) has been on the radar of many investment analysts in new situations, obtaining gained a collection of obtain ratings from top companies which includes Citigroup and Mizuho. These bullish sentiments crop up from the company’s economic technological know-how providers, which give fleet motor vehicle payment processing in addition to vacation and corporate alternatives, as properly as overall health and staff benefit options.

WEX’s Fleet Options phase gives a assortment of providers, ranging from shopper account activation and retention assist to merchant analytics answers with obtain to net-centered details analytics platforms. Furthermore, the section supplies ancillary providers and resources to enable fleets regulate expenses and funds prerequisites proficiently.

Although WEX’s one-yr small stands at $125.00 per share, its 1-calendar year large is drastically greater at $204.05 for each share. As of April 29, 2023, WEX shares opened at $173.29 for each share. The firm’s current market capitalization stands at an remarkable $7.42 billion, while its existing ratio and swift ratios stand at 1.08 each individual with a financial debt-to-fairness ratio of 1.53.

Modern insider transactions present that insiders have been providing WEX shares lately nevertheless, these transactions characterize considerably less than 1{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of all excellent shares owned by corporate insiders around the previous three months.

Big investors these types of as New York Condition Teachers Retirement Program and River Road Asset Management LLC have not long ago greater their stake in the corporation by 1.2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} and 11.8{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}, respectively.

In summary, even with some insider sell-offs just lately witnessed inside WEX, this does not just take absent from the company’s potential for advancement based mostly on consensus get rankings specified by market place-foremost firms these kinds of as Citigroup that have been raising their price tag targets considering the fact that February 2023 – indicating regular momentum toward positive prospective customers for extended-term traders who are ready to embrace the agency on this vivid journey.

March 6, 2023

Truist Financial analysts raised their price target on Broadcom (NASDAQ:AVGO) to $700.00.

In accordance to Benzinga, in a exploration notice dispersed to clientele and traders on Friday, Truist Money elevated its value objective for Broadcom (NASDAQ: AVGO) from $659.00 to $700.00.

The observe was distributed to buyers and investors.

At current, the organization has assigned the shares of the semiconductor company a rating of “buy,” indicating that they are favorable for invest in.

In accordance to the concentrate on selling price that Truist Economical founded, the organization has the possible to experience progress that is 16.93{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} larger than its most current closing price.

This information and facts was derived from the most modern closing cost.

Many studies, some of which are prolonged, have been created about AVGO. Some of these reviews go into substantial depth. Rosenblatt Securities reaffirmed its “buy” suggestion on shares of Broadcom and positioned them with a rate aim of $775.00 in a study report published on Wednesday. Raymond James advisable in a investigate be aware published on Thursday that buyers “market perform” about Broadcom shares.

This recommendation was reaffirmed by Raymond James. Susquehanna increased their rate aim on Broadcom from $650.00 to $685.00 and rated the business as “positive” in a research that was made public on Wednesday.

In a study report printed on Friday, Lender of The us upped its goal rate for Broadcom to $725.00, up from the preceding price of $680.00.

The most the latest information product is that on Tuesday, BNP Paribas posted a research observe stating that they would get started covering shares of Broadcom.

They prompt that the organization go after an “outperform” technique, and they proven a selling price goal of $660.00.

3 exploration analysts recommend preserving a hold place on the stock, seventeen gurus endorse buying the stock, and a person analyst endorses a sturdy invest in situation.

The organization now has an ordinary suggestion of “Moderate Get,” Bloomberg.com studies that the price that industry industry experts foresee it will reach in the not-much too-distant future is $676.81.
NASDAQ buying and selling in AVGO commenced Friday for $598.65 and continued through the day.

There is personal debt that is 1.72 moments as a lot as equity, a brief ratio of 2.35 occasions as substantially, and a current ratio of 2.62 periods as much.

It is at present approximated that the business has a industry capitalization of $249.59 billion and possesses a PE ratio of 22.59, an EG ratio of 1.24, and a beta worth of 1.10.

The moving regular for the inventory around the previous 50 days is $582.25, and the relocating regular about the past 200 times is $529.10.

This website page lists Broadcom’s 52-7 days small price, which was $415.07, and its 52-week higher price tag, which was $645.31.

On March 2nd, Broadcom’s most current quarterly earnings report, which is traded on the NASDAQ less than the image AVGO, was built general public.

The corporation that creates semiconductors declared quarterly earnings of $10.33 for each share, $.95 increased than the consensus projection of analysts, which was $9.38 for every share.

Broadcom’s return on equity and internet margin came in at 70{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}, when the company’s web margin was 34.62{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}.

The company’s quarterly sales came in at $8.92 billion, considerably greater than the $8.90 billion that industry analysts had predicted would be for its revenue. When compared to the prior year’s final results for the exact same quarter, the current year’s earnings for each share are $7.68. As opposed to the past year’s results for the exact quarter, the company’s quarterly income amplified by 15.7{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. Provide-facet analysts forecast Broadcom will produce 37.28 pounds per share earnings in the course of the present-day economic 12 months.

In other information, director Justine Web page marketed 170 shares of the company’s stock on Tuesday, December 13th.

The transaction took spot throughout the standard buying and selling session.

It came out to a overall of 97,726.20 dollars for the rate of the shares, which performs out to $574.86 for every single share independently.

As a immediate result of the transaction, the director now owns 2,981 shares of the company’s inventory.

The whole worth of these shares is close to $1,713,657.66.

If you abide by this website link, you will be taken to the filing submitted to the Securities and Trade Commission, the place the transaction was mentioned, and it will consider you there promptly.

Insiders own 2.20 percent of the overall shares fantastic in the corporation.

Above the earlier several months, various hedge funds and other varieties of institutional investors have altered the sectors of the economic climate in which they maintain investments.

For the duration of the previous 3 months of 2018, Regal Expense Advisors LLC elevated the percentage of Broadcom stock owned by 8.6{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. Regal Expenditure Advisors LLC now owns 1,230 shares of the inventory held by the semiconductor company because of to the buy of 97 more shares throughout the most current fiscal period of time.

These shares have a merged marketplace benefit of $688,000. Voya Expense Administration LLC built a .8{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} obtain of additional Broadcom inventory for the duration of the fourth quarter, which enhanced the company’s ownership percentage. Voya Investment Management LLC is now the proprietor of a whole of 2,223,618 shares of the stock held by the semiconductor producer.

These shares have a market place value of $1,243,292,000 immediately after the corporation designed an more purchase of 17,358 through the previous quarter.

For the duration of the last three months of 2018, Have faith in Investment decision Advisors completed a 6.5{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} raise in Broadcom inventory in its portfolio.

The value of Rely on Investment decision Advisors’ current holdings in the semiconductor manufacturer’s stock arrives to a overall of $1,495,000.

The company presently possesses 2,673 shares of the company’s stock.

This represents an maximize of 163 shares bought through the most new quarter of the company’s existence. Cascade Financial investment Group, INC accomplished the acquire of a new position in Broadcom in the course of the fourth quarter of 2018, paying somewhere around $327,000 for it.

And eventually, all through the past three months of 2018, Cravens & Co Advisors LLC built a new expenditure of about $170,000 in Broadcom.

This expenditure was built all through the Broadcom fourth quarter.

Institutional buyers and hedge funds collectively personal 81.28{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the overall amount of shares in the company, building up the majority of the shareholders.

February 20, 2023

Truist Financial analysts raised their price target on Owens Corning (NYSE:OC) to $105.00.

The equity analysts at Truist Financial elevated their target price for Owens Corning (NYSE: OC) from $85.00 to $105.00 based on research that was created community on Friday. When in contrast to the stock’s selling price as of appropriate now, which is 3.27 percent, the cost objective that Truist Money has established for itself signifies that there is the possibility of a value enhance.

Recently, the firm has had comments from a plethora of additional inventory research experts who have presented their input.

Loop Cash amplified its rate aim on Owens Corning to $125.00, up from the preceding selling price of $102.00, which was mentioned in a investigate notice that was designed public on Thursday.

In a study note revealed on October 27, Credit score Suisse Team lowered their “neutral” ranking on Owens Corning inventory and lowered their cost goal from $98.00 to $90.00.

Furthermore, they lessened their rate concentrate on on the stock from $90.00 to $80.00. On January 10, Citigroup elevated its value objective for Owens Corning shares from $88.00 to $90.00.

The earlier rate goal experienced been set at $88.00.

The Royal Lender of Canada elevated its value estimate for Owens Corning shares from $90.00 to $90.00 in a research report posted on Thursday.

The report was released in Canada.

The value aim for Owens Corning was reduced from $90.00 to $80.00 because of to a research that Barclays released on December 14, 2018. Six exploration analysts recommend getting the inventory, 7 say to preserve their current positions, and two field experts say to promote the stock.

In accordance to the facts identified on Bloomberg.com, the users of that website have assigned the firm a score of “Hold” and have founded an average selling price goal of $103.14 for the inventory.
OC commenced investing at $101.68 on Friday.

The price tag-to-earnings ratio for the enterprise is 8.02, the cost-to-earnings-to-development ratio is 1.80, and the beta value for the corporation is 1.45.

The organization has a market capitalization of $9.50 billion as of ideal now.

The credit card debt-to-fairness ratio is calculated to be .65, the recent ratio is calculated to be 1.69, and the swift ratio is calculated to be 1.11.

All through a year, the selling price of Owens Corning can fluctuate anyplace from $72.97 to $105.62, dependent on the get dimensions.

According to the easy going average of the past 200 days, the stock rate is at this time $88.26, but according to the simple going normal of the previous 50 days, the inventory value is currently $92.50.

Owens Corning (NYSE: OC) disseminated its report on the company’s functionality on February 15.

The building company’s most modern quarterly earnings for every share (EPS) came in at $2.49, which is $.15 better than the consensus estimate of $2.34, which was derived from analyst projections.

In addition to having a return on equity of 27.36{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}, Owens Corning efficiently realized a net margin of 12.71 p.c.

The business outperformed analysts’ projections for its quarterly profits, bringing in $2.29 billion instead of the $2.24 billion they anticipated.

The corporation recorded a revenue of $2.20 for every share in the exact same time period the year just before.

The most new quarterly report reveals that the company’s earnings improved by 7.2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} through the reporting period.

Fairness analysis specialists anticipate that Owens Corning will produce income of 10.04 cents per share through the existing fiscal yr.

On Friday, December 9, Vice President Kelly Schmidt sold 2,181 shares of the company’s inventory. Other objects relating to this topic ended up also mentioned.

The sale of the shares brought in a complete of $204,446.94, and the price tag paid for each share, on average, was $93.74.

December 3, 2022

AerSale (NASDAQ:ASLE) Now Covered by Analysts at Truist Financial

Truist Economical began coverage on shares of AerSale (NASDAQ:ASLE – Get Rating) in a analysis observe issued on Friday, The Fly stories. The business set a “purchase” score on the inventory.

Quite a few other analysts have also a short while ago issued reviews on ASLE. Stifel Nicolaus started protection on shares of AerSale in a study note on Thursday, September 1st. They issued a “obtain” ranking and a $23.00 target cost on the inventory. Royal Financial institution of Canada started coverage on shares of AerSale in a report on Tuesday. They issued an “outperform” ranking and a $21.00 cost focus on on the inventory. Last but not least, Cowen improved their price tag goal on shares of AerSale to $20.00 in a report on Monday, August 15th.

AerSale Price tag Functionality

NASDAQ ASLE opened at $15.77 on Friday. AerSale has a 1 year low of $12.78 and a 1 year substantial of $21.76. The inventory has a market place capitalization of $816.57 million, a PE ratio of 19.00 and a beta of .42. The company’s 50 working day very simple shifting normal is $18.25 and its two-hundred day easy relocating common is $17.34.

Insider Transactions at AerSale

In linked information, Director Jonathan A. Seiffer offered 4,452,249 shares of the inventory in a transaction on Friday, November 18th. The shares ended up bought at an typical rate of $14.80, for a full transaction of $65,893,285.20. Next the transaction, the director now owns 19,133,741 shares of the firm’s stock, valued at close to $283,179,366.80. The transaction was disclosed in a lawful submitting with the SEC, which is obtainable as a result of the SEC site. Insiders have 79.20{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the company’s stock.

Hedge Money Weigh In On AerSale

Institutional buyers and hedge funds have lately built adjustments to their positions in the organization. New York Point out Academics Retirement Method grew its holdings in shares of AerSale by 75.{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} for the duration of the 3rd quarter. New York State Instructors Retirement System now owns 1,400 shares of the firm’s inventory valued at $26,000 immediately after getting an added 600 shares for the duration of the very last quarter. Ensign Peak Advisors Inc bought a new stake in AerSale in the 3rd quarter worth $30,000. Captrust Monetary Advisors grew its holdings in AerSale by 26.2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the 2nd quarter. Captrust Monetary Advisors now owns 3,010 shares of the company’s stock worth $44,000 immediately after attaining an extra 625 shares all through the last quarter. Tower Research Money LLC TRC grew its holdings in AerSale by 267.8{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the 3rd quarter. Tower Investigate Funds LLC TRC now owns 3,435 shares of the company’s inventory well worth $63,000 following obtaining an added 2,501 shares all through the previous quarter. Eventually, Russell Investments Group Ltd. purchased a new stake in AerSale in the 2nd quarter worthy of $66,000.

About AerSale

(Get Score)

AerSale Corporation presents aftermarket business plane, engines, and its elements to passenger and cargo airlines, leasing firms, primary tools makers, and government and protection contractors, as nicely as routine maintenance, maintenance, and overhaul (MRO) assistance suppliers globally. It operates in two segments, Asset Administration Answers and Specialized Operations (TechOps).

Featured Stories

This instant news alert was generated by narrative science technological innovation and monetary info from MarketBeat in order to provide visitors with the quickest and most precise reporting. This tale was reviewed by MarketBeat’s editorial staff prior to publication. Be sure to send out any queries or reviews about this tale to speak to@marketbeat.com.

In advance of you take into account AerSale, you’ll want to hear this.

MarketBeat retains observe of Wall Street’s major-rated and finest carrying out exploration analysts and the shares they suggest to their shoppers on a daily basis. MarketBeat has discovered the 5 stocks that best analysts are quietly whispering to their consumers to obtain now before the broader marketplace catches on… and AerSale wasn’t on the record.

While AerSale at present has a “Purchase” ranking amongst analysts, top-rated analysts consider these 5 stocks are much better purchases.

Look at The Five Stocks Here

November 4, 2022

Truist Financial analysts rate Evolent Health (NYSE:EVH) as a hold.

A research note made public on Tuesday reported that Truist Financial had become a new shareholder in Evolent Health (NYSE: EVH). It was The Fly that provided us with the information. The stock of the information technology company has been given a “hold” rating, and the brokerage firm has established a price objective of $33.00 for the stock. The fact that the target price proposed by Truist Financial is higher than the current price of the stock, which is 3.74{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}, indicates that there is room for growth in the market for the stock.

In addition, the organization has been the focus of attention for earlier research investigations carried out by various analysts. In a research report published on Wednesday, October 12, Canaccord Genuity Group announced that they would be lowering their price objective for Evolent Health from $55.00 to $48:00. The report was issued on Wednesday. The “buy” rating and target price of $55.00 that BTIG Research had previously assigned to Evolent Health was reduced to $45.00 in a research report published on October 12. In a research report published on August 3, Evolent Health went from an “underweight” rating to a “neutral” rating and raised their target price on the stock from $35.00 to $40.00 in a research report that was published on August 3. Piper Jaffray also increased its target price on the stock. In a study published on July 25, Cowen announced that they would be increasing their target price for Evolent Health to $52.00. In a report published on Wednesday, October 12, Canaccord Genuity Group lowered their recommendation on Evolent Health from a “buy” rating to a “hold” rating in a report that was Despite this change; they did not change their price target from $55.00. Ten analysts have recommended purchasing the stock, while only two have recommended maintaining the current position in the stock. The current average rating for Evolent Health is “Moderate Buy,” and the price target is $46.09 per share, according to information that Bloomberg provided.
As trading got underway on Tuesday, the price of a share of Evolent Health was $31.81 per share. The stock currently trades at a market value of $2.91 billion and carries a price-to-earnings ratio of -99.41. It has a beta value of 1.70. The stock’s price is currently trading at $35.31 according to its fifty-day simple moving average, while its 200-day simple moving average can be found at $32.38. The ratio of total assets to current assets is 1.23, the ratio of current assets to total assets is also 1.23, and the ratio of debt to equity is 0.46. During the previous calendar year, Evolent Health’s price fluctuated between $21.36 and $39.78.

Evolent Health (NYSE: EVH) made the most recent quarterly earnings report available to the public on Tuesday, August 2, 2018, which was also a Tuesday. The information technology company’s earnings per share for the quarter came in at $0.02, which was $0.07 higher than the analysts’ consensus estimate of $0.05, which the company had provided. Even though market watchers anticipated that the company would bring in sales totaling $293.31 million during the quarter, the actual amount it brought in was $319.94 million. Evolent Health had a negative net margin of 2.63{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}, while the return on equity for the company was positive at 0.41{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. Sell-side analysts predict Evolent Health will make $0.056 per share in profits during the current fiscal year.

On Friday, August 12, Jonathan Weinberg, who serves as general counsel for Evolent Health, exercised his option to sell 14,335 shares of the company’s stock. Jonathan Weinberg exercised his option to sell 14,335 shares of the company’s stock. The sale of the stock resulted in a total revenue of 501,151.60 dollars and an average price of $34.96 per share for each purchased share. The general counsel is now the proud owner of 135,103 shares of company stock, which have a combined value of approximately $4,723,200.88 as a direct result of the transaction that took place earlier. If you follow this link, you will be taken to a document submitted to the Securities and Exchange Commission (SEC). The document contains an in-depth explanation of the reported transaction to the SEC. On Friday, August 12, Jonathan Weinberg, who serves as general counsel for Evolent Health, exercised his option to sell 14,335 shares of the company’s stock. Jonathan Weinberg exercised his option to sell 14,335 shares of the company’s stock.
A total of shares sold were worth $501,151.60 dollars, and the average price that each share was sold for was $34.96. The general counsel now has ownership of 135,103 business shares that have a combined value of $4,723,200.88 as a result of the successful completion of the sale. If you follow this link, you will be taken to the filing submitted to the Securities and Exchange Commission, where the transaction was discussed. You can simply ignore this link if you do not want to follow it. In addition, Mary Bridget Duffy, a company director, sold 7,500 shares of the company’s stock on Tuesday, August 16. The total amount received for the sale of the shares was $248,475.00, and the price paid on average for each share was $33.13. When the transaction is finalized, the director will have obtained 50,450 shares. Based on the current market price, this amount of stock is estimated to be worth $1,671,408.50. Disclosures that are related to the sale might be found in this section of the website. During the most recent quarter of the company’s fiscal year, company insiders sold 90,269 shares of company stock for a total price of $3,238,910. At present, company insiders collectively own 4.20{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the total number of shares outstanding.

Recently, several hedge funds and institutional investors have adjusted the total amount of stock held in their portfolios by either increasing or decreasing the amount of stock they hold. The amount of Evolent Health stock owned by Captrust Financial Advisors increased by 254.4{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} during the second quarter of the current fiscal year. In the most recent fiscal quarter, Captrust Financial Advisors increased their holdings in the technology company’s stock by purchasing an additional 1,262 shares. This brings their total holdings to 1,758 shares of the company’s stock, which has a value of $54,000. In the first three months of 2018, Nisa Investment Advisors LLC made a 67.9{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} purchase of additional Evolent Health stock, increasing the percentage of the company’s stock it owned. Nisa Investment Advisors LLC now holds a total of 2,250 shares of the technology company’s stock, which has a value of $73,000. This is a result of the purchase of an additional 910 shares during the most recent fiscal quarter. During the first three months of the year, AdvisorShares Investments LLC acquired a new position in shares of Evolent Health at a value of approximately $192,000. Oppenheimer & Co., Inc. increased its overall holdings in Evolent Health during the first quarter by investing approximately 206,000 additional dollars in the company through new investments. This is the final and most important point that needs to be made, as it relates to the fact that Convergence Investment Partners LLC increased its holdings in Evolent Health by approximately $228,000 during the first quarter. The stock is held by hedge funds and other institutional investors for 96.81{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of its total value, making these investors the most valuable shareholders.

Evolent Health LLC, a wholly owned subsidiary of Evolent Health, is a company that delivers clinical and administrative solutions to payers and providers in the United States. Evolent Health, Inc. is a company that operates in the healthcare industry. The business is organized into two distinct branches: the Evolent Health Services Division and the Clinical Solutions Branch. Evolent Health Services offers a complete administrative and clinical platform that can be used to run health plans and manage the overall health of a population.

April 4, 2022

Truist Financial Analysts Boost Earnings Estimates for Adicet Bio, Inc. (NASDAQ:ACET)

Adicet Bio, Inc. (NASDAQ:ACET – Get Rating) – Stock analysts at Truist Financial upped their Q1 2022 earnings per share (EPS) estimates for Adicet Bio in a report issued on Thursday, March 31st. Truist Financial analyst A. Goonewardene now expects that the company will earn $0.08 per share for the quarter, up from their previous forecast of $0.07. Truist Financial currently has a “Buy” rating and a $30.00 target price on the stock. Truist Financial also issued estimates for Adicet Bio’s Q4 2022 earnings at $2.25 EPS, FY2022 earnings at $1.61 EPS and FY2026 earnings at $2.07 EPS.

A number of other analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Adicet Bio from a “sell” rating to a “hold” rating in a research report on Tuesday, January 11th. Jefferies Financial Group began coverage on shares of Adicet Bio in a research report on Friday, March 4th. They issued a “buy” rating and a $27.00 target price on the stock. TheStreet upgraded shares of Adicet Bio from a “d” rating to a “c-” rating in a research report on Friday, December 17th. StockNews.com began coverage on shares of Adicet Bio in a research report on Thursday. They issued a “sell” rating on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of Adicet Bio in a research report on Tuesday, December 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $27.63.

(Ad)

Could This New Year Bring In Big Returns For Investors? Find Out More About This Booming..

NASDAQ ACET opened at $20.81 on Monday. The firm has a market capitalization of $829.84 million, a price-to-earnings ratio of -10.05 and a beta of 2.48. The firm’s 50 day simple moving average is $14.41 and its 200 day simple moving average is $12.28. Adicet Bio has a 1 year low of $6.25 and a 1 year high of $21.00. Adicet Bio (NASDAQ:ACET – Get Rating) last posted its quarterly earnings results on Tuesday, March 15th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.03). The company had revenue of $5.47 million for the quarter, compared to analyst estimates of $4.65 million.

In related news, Director Aya Jakobovits sold 8,000 shares of Adicet Bio stock in a transaction on Wednesday, February 9th. The shares were sold at an average price of $14.03, for a total transaction of $112,240.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 16,000 shares of company stock valued at $239,240 in the last three months. 33.90{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Abingworth LLP raised its stake in Adicet Bio by 31.0{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} during the fourth quarter. Abingworth LLP now owns 2,115,385 shares of the company’s stock worth $36,892,000 after buying an additional 500,000 shares during the last quarter. BlackRock Inc. grew its holdings in Adicet Bio by 16.3{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the fourth quarter. BlackRock Inc. now owns 1,452,452 shares of the company’s stock worth $25,403,000 after purchasing an additional 203,933 shares during the period. Point72 Asset Management L.P. grew its holdings in Adicet Bio by 4.9{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the third quarter. Point72 Asset Management L.P. now owns 1,275,000 shares of the company’s stock worth $9,996,000 after purchasing an additional 60,000 shares during the period. DAFNA Capital Management LLC grew its holdings in Adicet Bio by 94.8{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the fourth quarter. DAFNA Capital Management LLC now owns 733,172 shares of the company’s stock worth $12,823,000 after purchasing an additional 356,891 shares during the period. Finally, Johnson & Johnson acquired a new stake in Adicet Bio in the third quarter worth $5,715,000. 68.55{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the stock is owned by institutional investors and hedge funds.

Adicet Bio Company Profile (Get Rating)

Adicet Bio, Inc is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Adicet Bio right now?

Before you consider Adicet Bio, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Adicet Bio wasn’t on the list.

While Adicet Bio currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here